Neutral
AI recommendation signal analysis across 307 domains for the Neutral persona in Weight Loss Clinics GLP-1 Telehealth.
This report tracks how AI models and search engines recommend companies across 100 industries. If you want the same analysis run specifically against your own site and competitors, get in touch.
Get in touch →How to use this page
Build your outreach list
The blogs, publishers, and newsletters that cover this space. Pitch guest content, sponsorships, and PR to the ones that keep ranking.
Where the numbers come from
We run blogs, publishers, newsletters queries for this industry through Google and aggregate every result: domains by rank-weighted score (higher positions count for more) and appearance count, exact URLs by appearance count, and the most common title phrases.
What's on this page
Domain and URL charts, the full result list, and title n-gram tables.
Research: Blogs, Publishers, Newsletters
Domains appearing in Google results for Neutral's Research: Blogs, Publishers, Newsletters queries. Score is a rank-weighted sum (higher-ranked appearances count for more); count is a plain appearance tally.
Top URLs
Individual pages (not just domains) ranked by the same rank-weighted score, labeled by page title.
All Results
Every result for Neutral's Research: Blogs, Publishers, Newsletters queries, ranked by how many times each exact URL appeared (ties broken by average rank position, so appearing higher up wins), a different aggregation than the score-based charts above. Title and URL links open in a new tab.
Title N-Grams
Most common word phrases (2 to 7 words) across every result title for these queries.
2-grams
| 123 | glp 1 |
| 85 | weight loss |
| 36 | glp 1s |
| 24 | 1 weight |
| 20 | loss drugs |
| 16 | for weight |
| 14 | of glp |
| 13 | with glp |
| 13 | 1 drugs |
| 11 | 1 medications |
| 8 | 1 agonists |
| 8 | here s |
| 8 | weight with |
| 6 | the glp |
| 6 | about glp |
| 6 | 1s for |
| 6 | how glp |
| 6 | don t |
| 6 | t lose |
| 6 | lose weight |
| 6 | 1s evidence |
| 6 | of weight |
| 5 | to glp |
| 5 | for women |
| 5 | beyond weight |
3-grams
| 24 | glp 1 weight |
| 21 | 1 weight loss |
| 20 | weight loss drugs |
| 15 | for weight loss |
| 13 | glp 1 drugs |
| 11 | glp 1 medications |
| 9 | of glp 1 |
| 8 | glp 1 agonists |
| 8 | weight with glp |
| 7 | with glp 1 |
| 6 | the glp 1 |
| 6 | glp 1s for |
| 6 | t lose weight |
| 6 | with glp 1s |
| 6 | glp 1s evidence |
| 6 | of weight loss |
| 5 | 1s for weight |
| 5 | some people don |
| 5 | people don t |
| 5 | don t lose |
| 5 | lose weight with |
| 5 | 1s evidence is |
| 4 | and weight loss |
| 4 | to glp 1 |
| 4 | beyond weight loss |
4-grams
| 21 | glp 1 weight loss |
| 7 | 1 weight loss drugs |
| 6 | weight with glp 1s |
| 6 | with glp 1s evidence |
| 5 | glp 1s for weight |
| 5 | 1s for weight loss |
| 5 | some people don t |
| 5 | people don t lose |
| 5 | don t lose weight |
| 5 | t lose weight with |
| 5 | lose weight with glp |
| 5 | glp 1s evidence is |
| 5 | of weight loss drugs |
| 4 | food companies are targeting |
| 4 | companies are targeting users |
| 4 | are targeting users of |
| 4 | targeting users of weight |
| 4 | users of weight loss |
| 3 | agonists for weight loss |
| 3 | to glp 1 weight |
| 3 | of glp 1 agonists |
| 3 | new weight loss drugs |
| 3 | glp 1 receptor agonists |
| 3 | glp 1 medications are |
| 2 | with glp 1 agonists |
5-grams
| 7 | glp 1 weight loss drugs |
| 6 | weight with glp 1s evidence |
| 5 | glp 1s for weight loss |
| 5 | some people don t lose |
| 5 | people don t lose weight |
| 5 | don t lose weight with |
| 5 | t lose weight with glp |
| 5 | lose weight with glp 1s |
| 5 | with glp 1s evidence is |
| 4 | food companies are targeting users |
| 4 | companies are targeting users of |
| 4 | are targeting users of weight |
| 4 | targeting users of weight loss |
| 4 | users of weight loss drugs |
| 2 | glp 1 agonists for weight |
| 2 | 1 agonists for weight loss |
| 2 | guide to glp 1 weight |
| 2 | to glp 1 weight loss |
| 2 | glp 1 weight loss what |
| 2 | weight loss with glp 1 |
| 2 | glp 1 and health beyond |
| 2 | 1 and health beyond weight |
| 2 | and health beyond weight loss |
| 2 | health beyond weight loss in |
| 2 | beyond weight loss in the |
6-grams
| 5 | some people don t lose weight |
| 5 | people don t lose weight with |
| 5 | don t lose weight with glp |
| 5 | t lose weight with glp 1s |
| 5 | lose weight with glp 1s evidence |
| 5 | weight with glp 1s evidence is |
| 4 | food companies are targeting users of |
| 4 | companies are targeting users of weight |
| 4 | are targeting users of weight loss |
| 4 | targeting users of weight loss drugs |
| 2 | glp 1 agonists for weight loss |
| 2 | guide to glp 1 weight loss |
| 2 | glp 1 and health beyond weight |
| 2 | 1 and health beyond weight loss |
| 2 | and health beyond weight loss in |
| 2 | health beyond weight loss in the |
| 2 | beyond weight loss in the ozempic |
| 2 | weight loss in the ozempic era |
| 2 | how losing weight with glp 1 |
| 2 | losing weight with glp 1 changed |
| 2 | weight with glp 1 changed more |
| 2 | with glp 1 changed more than |
| 2 | glp 1 changed more than j |
| 2 | of glp 1 weight loss drugs |
| 2 | around half of patients discontinue glp |
7-grams
| 5 | some people don t lose weight with |
| 5 | people don t lose weight with glp |
| 5 | don t lose weight with glp 1s |
| 5 | t lose weight with glp 1s evidence |
| 4 | lose weight with glp 1s evidence is |
| 4 | food companies are targeting users of weight |
| 4 | companies are targeting users of weight loss |
| 4 | are targeting users of weight loss drugs |
| 2 | glp 1 and health beyond weight loss |
| 2 | 1 and health beyond weight loss in |
| 2 | and health beyond weight loss in the |
| 2 | health beyond weight loss in the ozempic |
| 2 | beyond weight loss in the ozempic era |
| 2 | how losing weight with glp 1 changed |
| 2 | losing weight with glp 1 changed more |
| 2 | weight with glp 1 changed more than |
| 2 | with glp 1 changed more than j |
| 2 | around half of patients discontinue glp 1s |
| 2 | half of patients discontinue glp 1s studies |
| 2 | of patients discontinue glp 1s studies show |
| 2 | glp 1 hub support community and weight |
| 2 | 1 hub support community and weight loss |
| 2 | world health organization recommends glp 1 drugs |
| 2 | medimpact redefines obesity care with new suite |
| 2 | redefines obesity care with new suite of |